Insurer Bargaining and Negotiated Drug Prices in Medicare Part D

Published in: NBER Working Papers / (Cambridge, MA: National Bureau of Economic Research, Sep. 2009), p. 1-35, 1-14

Posted on on January 01, 2009

by Darius N. Lakdawalla, Wesley Yin

Read More

Access further information on this document at

This article was published outside of RAND. The full text of the article can be found at the link above.

A controversial feature of Medicare Part D is its reliance on private insurers to negotiate drug prices and rebates with retail pharmacies and drug manufacturers. Central to this controversy is whether increases in market power-an undesirable feature in most settings-confer benefits in health insurance markets, where larger buyers may obtain better prices for their members. The authors test whether insurers that experience larger enrollment increases due to Part D negotiate lower drug prices with pharmacies. Overall, the authors find that 100,000 additional insureds lead to 2.5-percent lower pharmacy prices negotiated by the insurer, and 5-percent reductions in pharmacy profits earned on prescriptions filled by enrollees of that insurer. Estimated enrollment effects are much larger for drugs with therapeutic substitutes, and virtually zero for branded drugs without therapeutic substitutes. The authors also present evidence that most insurer savings are, on the margin, passed on as lower premiums. Out-of-sample estimation suggests that modest insurer consolidation would generate significant savings to Medicare, along with premium reductions and enrollment increases. Finally, the authors find that greater enrollment leads to lower pharmacy prices negotiated by insurers for their non-Part D market-an external benefit to the commercially enrolled associated with administering Part D through private insurers.

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.